PRKDC and neoplasm: Overall, a consistent and marked dose-dependent decrease in the PD biomarker level (p-DNA-PK/total DNA-PK ratio) was observed in PBMCs, as a surrogate of tumour tissue, at early time points (3 and 6 h) after peposertib administration (Fig. 3).